Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells.
Chemoresistance and radioresistance are considered one of the primary reasons for therapeutic failure in leukemias and solid tumors. Targeted radiotherapy using monoclonal antibodies radiolabeled with alpha-particles is a promising treatment approach for high-risk leukemia. We found that targeted radiotherapy using monoclonal CD45 antibodies radiolabeled with the alpha-emitter (213)Bi ([(213)Bi]anti-CD45) induces apoptosis, activates apoptosis pathways, and breaks beta-irradiation-, gamma-irradiation-, doxorubicin-, and apoptosis-resistance in leukemia cells. In contrast to beta-irradiation-, gamma-irradiation-, and doxorubicin-mediated apoptosis and DNA damage, [(213)Bi]anti-CD45-induced DNA damage was not repaired, and apoptosis was not inhibited by the nonhomologous end-joining DNA repair mechanism. Depending on the activation of caspase-3, caspase-8, and caspase-9, [(213)Bi]anti-CD45 activated apoptosis pathways in leukemia cells through the mitochondrial pathway but independent of CD95 receptor/CD95 ligand interaction. Furthermore, [(213)Bi]anti-CD45 reversed deficient activation of caspase-3, caspase-8, and caspase-9, deficient cleavage of poly(ADP-ribose) polymerase, and deficient activation of mitochondria in chemoresistant and in radioresistant and apoptosis-resistant leukemia cells. These findings show that [(213)Bi]anti-CD45 is a promising therapeutic agent to break chemoresistance and radioresistance by overcoming DNA repair mechanisms in leukemia cells and provide the foundation for discovery of novel anticancer compounds.
Friesen
Claudia
C
Nuclear Medicine Clinic, Department of Transfusion Medicine, and University Children's Hospital, University of Ulm, Ulm, Germany. claudia.friesen@uni-ulm.de
Glatting
Gerhard
G
Koop
Bernd
B
Schwarz
Klaus
K
Morgenstern
Alfred
A
Apostolidis
Christos
C
Debatin
Klaus-Michael
KM
Reske
Sven N
SN
D000906:Antibodies; D017209:Apoptosis / Q000528:radiation effects; D001729:Bismuth / Q000627:therapeutic use*; D020169:Caspases / Q000378:metabolism; D004260:DNA Repair / Q000528:radiation effects; D004273:DNA, Neoplasm / Q000528:radiation effects; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D018922:HL-60 Cells; D006801:Humans; D007938:Leukemia / Q000276:immunology / Q000532:radiotherapy*; D017493:Leukocyte Common Antigens / Q000276:immunology*; D008928:Mitochondria / Q000378:metabolism; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D011836:Radiation Tolerance / Q000276:immunology; D016499:Radioimmunotherapy; D011868:Radioisotopes / Q000627:therapeutic use*
D000906:Antibodies; D004273:DNA, Neoplasm; D011868:Radioisotopes; D004317:Doxorubicin; D011065:Poly(ADP-ribose) Polymerases; D017493:Leukocyte Common Antigens; C516769:PTPRC protein, human; D020169:Caspases; D001729:Bismuth